7160-44-3Relevant articles and documents
NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
-
Paragraph 3728-3730, (2015/10/05)
The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.
Auristatin derivatives and use thereof
-
Page/Page column, (2014/05/20)
The present application relates to novel derivatives of monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and also to the use of these derivatives for preparing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as, for example, cancerous disorders. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
Syntheses of conformationally constricted molecules as potential NAALADase/PSMA inhibitors
Ding, Pingyu,Miller, Marvin J.,Chen, Yi,Helquist, Paul,Oliver, A. Jayne,Wiest, Olaf
, p. 1805 - 1808 (2007/10/03)
Matrix presented. Two six-membered ring targeted analogues of PSMA inhibitors (4a and 4b) were designed on the basis of a computational analysis and synthesized. (E,Z)-Diene 10 was subjected to the nitroso Diels-Alder reaction to give the 1,4-trans six-me
